Le SIDA au Ghana (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Volunteer safer than replacement donor blood: a myth revealed by evidence

Identifieur interne : 000454 ( Istex/Corpus ); précédent : 000453; suivant : 000455

Volunteer safer than replacement donor blood: a myth revealed by evidence

Auteurs : J. Allain

Source :

RBID : ISTEX:6F12C11EABAC980E09EB31EBAB890601CC468C10

English descriptors

Abstract

The dogma that volunteer non‐remunerated blood donors (VNRD) are safer has been a cornerstone of world transfusion, including developing countries, for WHO and other major transfusion organizations although the data supporting this dogma has never been convincing. It was supported by data collected without regard for the basic rule of epidemiology, which is to compare what is comparable. In this case, first‐time and repeat VNRD were amalgamated, and genuine replacement/family donors (R/F) were mixed with paid donors. In sub‐Saharan Africa (SSA), VNRD and R/F donors have a median age of < 20 and around 30, respectively. In VNRD, the proportion of females is considerably higher than in R/F donors further distorting the comparisons. In epidemiological terms, only first‐time VNRD can be validly compared to R/F donors. When such valid approach is taken, as published by three SSA countries (Cameroon, Ghana and Guinea), no significant difference in the prevalence of anti‐HIV and HBsAg is apparent. In each study, first‐time VNRD > 20 years of age have higher prevalence of HBsAg and sometimes of anti‐HIV than R/F donors. These confirmed preliminary data strongly suggest that first‐time VNRD and R/F donors are epidemiologically undistinguishable and equally safe for viral infections. This collective data should directly impact three critical factors: the cost of blood, the availability of blood and the efforts put in recruiting repeat donors. R/F blood costs 2–5 times less than VNRD blood, and collecting R/F blood should no longer be discouraged. VNRD‐only policy not only costs more but also limits blood availability for acute anaemia, potentially endangering patients’ lives. Collecting R/F blood as a legitimate supplement to VNRD blood may help reaching 10 units/1000 inhabitants, a level considered adequate for developing countries’ blood supply. Only repeat donation significantly improves blood viral safety. As a result, not only first‐time VNRD but also R/F donors should be actively encouraged to repeat donation. Evidence should take precedence over a moribund myth.

Url:
DOI: 10.1111/j.1751-2824.2010.01423.x

Links to Exploration step

ISTEX:6F12C11EABAC980E09EB31EBAB890601CC468C10

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Volunteer safer than replacement donor blood: a myth revealed by evidence</title>
<author>
<name sortKey="Allain, J" sort="Allain, J" uniqKey="Allain J" first="J." last="Allain">J. Allain</name>
<affiliation>
<mods:affiliation>Transfusion Medicine, University of Cambridge, Cambridge, UK</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:6F12C11EABAC980E09EB31EBAB890601CC468C10</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1111/j.1751-2824.2010.01423.x</idno>
<idno type="url">https://api.istex.fr/document/6F12C11EABAC980E09EB31EBAB890601CC468C10/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000454</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000454</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">Volunteer safer than replacement donor blood: a myth revealed by evidence</title>
<author>
<name sortKey="Allain, J" sort="Allain, J" uniqKey="Allain J" first="J." last="Allain">J. Allain</name>
<affiliation>
<mods:affiliation>Transfusion Medicine, University of Cambridge, Cambridge, UK</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">ISBT Science Series</title>
<title level="j" type="sub">XXXIst International Congress of the ISBT</title>
<title level="j" type="alt">ISBT SCIENCE SERIES</title>
<idno type="ISSN">1751-2816</idno>
<idno type="eISSN">1751-2824</idno>
<imprint>
<biblScope unit="vol">5</biblScope>
<biblScope unit="issue">n1</biblScope>
<biblScope unit="page" from="169">169</biblScope>
<biblScope unit="page" to="175">175</biblScope>
<biblScope unit="page-count">7</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2010-07">2010-07</date>
</imprint>
<idno type="ISSN">1751-2816</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">1751-2816</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Africa region</term>
<term>African region</term>
<term>Allain</term>
<term>Blood centres</term>
<term>Blood collection</term>
<term>Blood donation</term>
<term>Blood donations</term>
<term>Blood donors</term>
<term>Blood safety</term>
<term>Blood services</term>
<term>Blood shortages</term>
<term>Blood supply</term>
<term>Blood transfusion</term>
<term>Burkina faso</term>
<term>Donation</term>
<term>Donor</term>
<term>Donors vnrd</term>
<term>Face value</term>
<term>Hbsag</term>
<term>Higher prevalence</term>
<term>International society</term>
<term>Isbt</term>
<term>Isbt science series</term>
<term>Journal compilation</term>
<term>Lower prevalence</term>
<term>Pepfar programme</term>
<term>Prevalence</term>
<term>Public sector</term>
<term>Replacement blood donors</term>
<term>Replacement donors</term>
<term>Secondary school</term>
<term>Small tokens</term>
<term>Subsaharan africa</term>
<term>Tayou tagny</term>
<term>Transfus clin biol</term>
<term>Transfusion</term>
<term>Transfusion requirements</term>
<term>Viral</term>
<term>Viral infections</term>
<term>Viral marker prevalence</term>
<term>Viral markers</term>
<term>Vnrd</term>
<term>Vnrd blood</term>
<term>Volunteer blood</term>
<term>Volunteer blood donors</term>
<term>Volunteer donors</term>
<term>West africa</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en">
<term>Africa region</term>
<term>African region</term>
<term>Allain</term>
<term>Blood centres</term>
<term>Blood collection</term>
<term>Blood donation</term>
<term>Blood donations</term>
<term>Blood donors</term>
<term>Blood safety</term>
<term>Blood services</term>
<term>Blood shortages</term>
<term>Blood supply</term>
<term>Blood transfusion</term>
<term>Burkina faso</term>
<term>Donation</term>
<term>Donor</term>
<term>Donors vnrd</term>
<term>Face value</term>
<term>Hbsag</term>
<term>Higher prevalence</term>
<term>International society</term>
<term>Isbt</term>
<term>Isbt science series</term>
<term>Journal compilation</term>
<term>Lower prevalence</term>
<term>Pepfar programme</term>
<term>Prevalence</term>
<term>Public sector</term>
<term>Replacement blood donors</term>
<term>Replacement donors</term>
<term>Secondary school</term>
<term>Small tokens</term>
<term>Subsaharan africa</term>
<term>Tayou tagny</term>
<term>Transfus clin biol</term>
<term>Transfusion</term>
<term>Transfusion requirements</term>
<term>Viral</term>
<term>Viral infections</term>
<term>Viral marker prevalence</term>
<term>Viral markers</term>
<term>Vnrd</term>
<term>Vnrd blood</term>
<term>Volunteer blood</term>
<term>Volunteer blood donors</term>
<term>Volunteer donors</term>
<term>West africa</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The dogma that volunteer non‐remunerated blood donors (VNRD) are safer has been a cornerstone of world transfusion, including developing countries, for WHO and other major transfusion organizations although the data supporting this dogma has never been convincing. It was supported by data collected without regard for the basic rule of epidemiology, which is to compare what is comparable. In this case, first‐time and repeat VNRD were amalgamated, and genuine replacement/family donors (R/F) were mixed with paid donors. In sub‐Saharan Africa (SSA), VNRD and R/F donors have a median age of < 20 and around 30, respectively. In VNRD, the proportion of females is considerably higher than in R/F donors further distorting the comparisons. In epidemiological terms, only first‐time VNRD can be validly compared to R/F donors. When such valid approach is taken, as published by three SSA countries (Cameroon, Ghana and Guinea), no significant difference in the prevalence of anti‐HIV and HBsAg is apparent. In each study, first‐time VNRD > 20 years of age have higher prevalence of HBsAg and sometimes of anti‐HIV than R/F donors. These confirmed preliminary data strongly suggest that first‐time VNRD and R/F donors are epidemiologically undistinguishable and equally safe for viral infections. This collective data should directly impact three critical factors: the cost of blood, the availability of blood and the efforts put in recruiting repeat donors. R/F blood costs 2–5 times less than VNRD blood, and collecting R/F blood should no longer be discouraged. VNRD‐only policy not only costs more but also limits blood availability for acute anaemia, potentially endangering patients’ lives. Collecting R/F blood as a legitimate supplement to VNRD blood may help reaching 10 units/1000 inhabitants, a level considered adequate for developing countries’ blood supply. Only repeat donation significantly improves blood viral safety. As a result, not only first‐time VNRD but also R/F donors should be actively encouraged to repeat donation. Evidence should take precedence over a moribund myth.</div>
</front>
</TEI>
<istex>
<corpusName>wiley</corpusName>
<keywords>
<teeft>
<json:string>vnrd</json:string>
<json:string>transfusion</json:string>
<json:string>hbsag</json:string>
<json:string>blood transfusion</json:string>
<json:string>allain</json:string>
<json:string>viral</json:string>
<json:string>donor</json:string>
<json:string>blood safety</json:string>
<json:string>replacement donors</json:string>
<json:string>blood donors</json:string>
<json:string>donation</json:string>
<json:string>blood supply</json:string>
<json:string>journal compilation</json:string>
<json:string>isbt science series</json:string>
<json:string>international society</json:string>
<json:string>isbt</json:string>
<json:string>volunteer blood donors</json:string>
<json:string>vnrd blood</json:string>
<json:string>blood donation</json:string>
<json:string>viral markers</json:string>
<json:string>blood centres</json:string>
<json:string>burkina faso</json:string>
<json:string>higher prevalence</json:string>
<json:string>blood shortages</json:string>
<json:string>blood donations</json:string>
<json:string>blood services</json:string>
<json:string>lower prevalence</json:string>
<json:string>viral infections</json:string>
<json:string>prevalence</json:string>
<json:string>blood collection</json:string>
<json:string>volunteer donors</json:string>
<json:string>secondary school</json:string>
<json:string>africa region</json:string>
<json:string>volunteer blood</json:string>
<json:string>public sector</json:string>
<json:string>viral marker prevalence</json:string>
<json:string>donors vnrd</json:string>
<json:string>face value</json:string>
<json:string>pepfar programme</json:string>
<json:string>small tokens</json:string>
<json:string>transfusion requirements</json:string>
<json:string>subsaharan africa</json:string>
<json:string>replacement blood donors</json:string>
<json:string>west africa</json:string>
<json:string>tayou tagny</json:string>
<json:string>transfus clin biol</json:string>
<json:string>african region</json:string>
</teeft>
</keywords>
<author>
<json:item>
<name>J.‐P. Allain</name>
<affiliations>
<json:string>Transfusion Medicine, University of Cambridge, Cambridge, UK</json:string>
</affiliations>
</json:item>
</author>
<subject>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>blood donor</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>blood supply</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>replacement</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>sub‐Saharan Africa</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>volunteer</value>
</json:item>
</subject>
<articleId>
<json:string>VOXS1423</json:string>
</articleId>
<language>
<json:string>eng</json:string>
</language>
<originalGenre>
<json:string>article</json:string>
</originalGenre>
<abstract>The dogma that volunteer non‐remunerated blood donors (VNRD) are safer has been a cornerstone of world transfusion, including developing countries, for WHO and other major transfusion organizations although the data supporting this dogma has never been convincing. It was supported by data collected without regard for the basic rule of epidemiology, which is to compare what is comparable. In this case, first‐time and repeat VNRD were amalgamated, and genuine replacement/family donors (R/F) were mixed with paid donors. In sub‐Saharan Africa (SSA), VNRD and R/F donors have a median age of > 20 and around 30, respectively. In VNRD, the proportion of females is considerably higher than in R/F donors further distorting the comparisons. In epidemiological terms, only first‐time VNRD can be validly compared to R/F donors. When such valid approach is taken, as published by three SSA countries (Cameroon, Ghana and Guinea), no significant difference in the prevalence of anti‐HIV and HBsAg is apparent. In each study, first‐time VNRD > 20 years of age have higher prevalence of HBsAg and sometimes of anti‐HIV than R/F donors. These confirmed preliminary data strongly suggest that first‐time VNRD and R/F donors are epidemiologically undistinguishable and equally safe for viral infections. This collective data should directly impact three critical factors: the cost of blood, the availability of blood and the efforts put in recruiting repeat donors. R/F blood costs 2–5 times less than VNRD blood, and collecting R/F blood should no longer be discouraged. VNRD‐only policy not only costs more but also limits blood availability for acute anaemia, potentially endangering patients’ lives. Collecting R/F blood as a legitimate supplement to VNRD blood may help reaching 10 units/1000 inhabitants, a level considered adequate for developing countries’ blood supply. Only repeat donation significantly improves blood viral safety. As a result, not only first‐time VNRD but also R/F donors should be actively encouraged to repeat donation. Evidence should take precedence over a moribund myth.</abstract>
<qualityIndicators>
<score>6.909</score>
<pdfVersion>1.3</pdfVersion>
<pdfPageSize>595.276 x 799.37 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<abstractCharCount>2095</abstractCharCount>
<pdfWordCount>3909</pdfWordCount>
<pdfCharCount>23498</pdfCharCount>
<pdfPageCount>7</pdfPageCount>
<abstractWordCount>313</abstractWordCount>
</qualityIndicators>
<title>Volunteer safer than replacement donor blood: a myth revealed by evidence</title>
<genre>
<json:string>article</json:string>
</genre>
<host>
<title>ISBT Science Series</title>
<language>
<json:string>unknown</json:string>
</language>
<doi>
<json:string>10.1111/(ISSN)1751-2824</json:string>
</doi>
<issn>
<json:string>1751-2816</json:string>
</issn>
<eissn>
<json:string>1751-2824</json:string>
</eissn>
<publisherId>
<json:string>VOXS</json:string>
</publisherId>
<volume>5</volume>
<issue>n1</issue>
<pages>
<first>169</first>
<last>175</last>
<total>7</total>
</pages>
<genre>
<json:string>journal</json:string>
</genre>
</host>
<categories>
<inist>
<json:string>sciences appliquees, technologies et medecines</json:string>
<json:string>sciences biologiques et medicales</json:string>
<json:string>sciences medicales</json:string>
</inist>
</categories>
<publicationDate>2010</publicationDate>
<copyrightDate>2010</copyrightDate>
<doi>
<json:string>10.1111/j.1751-2824.2010.01423.x</json:string>
</doi>
<id>6F12C11EABAC980E09EB31EBAB890601CC468C10</id>
<score>1</score>
<fulltext>
<json:item>
<extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/document/6F12C11EABAC980E09EB31EBAB890601CC468C10/fulltext/pdf</uri>
</json:item>
<json:item>
<extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/document/6F12C11EABAC980E09EB31EBAB890601CC468C10/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/6F12C11EABAC980E09EB31EBAB890601CC468C10/fulltext/tei">
<teiHeader>
<fileDesc>
<titleStmt>
<title level="a" type="main">Volunteer safer than replacement donor blood: a myth revealed by evidence</title>
</titleStmt>
<publicationStmt>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<availability>
<licence>© 2010 The Author. Journal compilation © 2010 International Society of Blood Transfusion</licence>
</availability>
<date type="published" when="2010-07"></date>
</publicationStmt>
<notesStmt>
<note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note>
<note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc>
<biblStruct type="article">
<analytic>
<title level="a" type="main">Volunteer safer than replacement donor blood: a myth revealed by evidence</title>
<title level="a" type="short">A myth revealed by evidence</title>
<author xml:id="author-0000">
<persName>
<forename type="first">J.‐P.</forename>
<surname>Allain</surname>
</persName>
<affiliation>Transfusion Medicine, University of Cambridge, Cambridge, UK
<address>
<country key="GB"></country>
</address>
</affiliation>
</author>
<idno type="istex">6F12C11EABAC980E09EB31EBAB890601CC468C10</idno>
<idno type="DOI">10.1111/j.1751-2824.2010.01423.x</idno>
<idno type="unit">VOXS1423</idno>
<idno type="toTypesetVersion">file:VOXS.VOXS1423.pdf</idno>
</analytic>
<monogr>
<title level="j" type="main">ISBT Science Series</title>
<title level="j" type="sub">XXXIst International Congress of the ISBT</title>
<title level="j" type="alt">ISBT SCIENCE SERIES</title>
<idno type="pISSN">1751-2816</idno>
<idno type="eISSN">1751-2824</idno>
<idno type="book-DOI">10.1111/(ISSN)1751-2824</idno>
<idno type="book-part-DOI">10.1111/voxs.2010.5.issue-n1</idno>
<idno type="product">VOXS</idno>
<idno type="publisherDivision">ST</idno>
<imprint>
<biblScope unit="vol">5</biblScope>
<biblScope unit="issue">n1</biblScope>
<biblScope unit="page" from="169">169</biblScope>
<biblScope unit="page" to="175">175</biblScope>
<biblScope unit="page-count">7</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2010-07"></date>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<abstract xml:lang="en" style="main">
<p>The dogma that volunteer non‐remunerated blood donors (VNRD) are safer has been a cornerstone of world transfusion, including developing countries, for WHO and other major transfusion organizations although the data supporting this dogma has never been convincing. It was supported by data collected without regard for the basic rule of epidemiology, which is to compare what is comparable. In this case, first‐time and repeat VNRD were amalgamated, and genuine replacement/family donors (R/F) were mixed with paid donors. In sub‐Saharan Africa (SSA), VNRD and R/F donors have a median age of < 20 and around 30, respectively. In VNRD, the proportion of females is considerably higher than in R/F donors further distorting the comparisons. In epidemiological terms, only first‐time VNRD can be validly compared to R/F donors.</p>
<p>When such valid approach is taken, as published by three SSA countries (Cameroon, Ghana and Guinea), no significant difference in the prevalence of anti‐HIV and HBsAg is apparent. In each study, first‐time VNRD > 20 years of age have higher prevalence of HBsAg and sometimes of anti‐HIV than R/F donors. These confirmed preliminary data strongly suggest that first‐time VNRD and R/F donors are epidemiologically undistinguishable and equally safe for viral infections.</p>
<p>This collective data should directly impact three critical factors: the cost of blood, the availability of blood and the efforts put in recruiting repeat donors. R/F blood costs 2–5 times less than VNRD blood, and collecting R/F blood should no longer be discouraged. VNRD‐only policy not only costs more but also limits blood availability for acute anaemia, potentially endangering patients’ lives. Collecting R/F blood as a legitimate supplement to VNRD blood may help reaching 10 units/1000 inhabitants, a level considered adequate for developing countries’ blood supply.</p>
<p>Only repeat donation significantly improves blood viral safety. As a result, not only first‐time VNRD but also R/F donors should be actively encouraged to repeat donation. Evidence should take precedence over a moribund myth.</p>
</abstract>
<textClass>
<keywords xml:lang="en">
<term xml:id="k1">blood donor</term>
<term xml:id="k2">blood supply</term>
<term xml:id="k3">replacement</term>
<term xml:id="k4">sub‐Saharan Africa</term>
<term xml:id="k5">volunteer</term>
</keywords>
<classCode scheme="tocHeading1">XXXIst International Congress of the ISBT, Berlin, Germany, 26 June‐1 July 2010</classCode>
<classCode scheme="tocHeading2">State of the Art Presentations</classCode>
</textClass>
<langUsage>
<language ident="EN"></language>
</langUsage>
</profileDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item>
<extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/document/6F12C11EABAC980E09EB31EBAB890601CC468C10/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata>
<istex:metadataXml wicri:clean="Wiley, elements deleted: body">
<istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document>
<component version="2.0" type="serialArticle" xml:lang="en">
<header>
<publicationMeta level="product">
<publisherInfo>
<publisherName>Blackwell Publishing Ltd</publisherName>
<publisherLoc>Oxford, UK</publisherLoc>
</publisherInfo>
<doi origin="wiley" registered="yes">10.1111/(ISSN)1751-2824</doi>
<issn type="print">1751-2816</issn>
<issn type="electronic">1751-2824</issn>
<idGroup>
<id type="product" value="VOXS"></id>
<id type="publisherDivision" value="ST"></id>
</idGroup>
<titleGroup>
<title type="main" sort="ISBT SCIENCE SERIES">ISBT Science Series</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="07000">
<doi origin="wiley">10.1111/voxs.2010.5.issue-n1</doi>
<titleGroup>
<title type="specialIssueTitle">XXXIst International Congress of the ISBT</title>
</titleGroup>
<numberingGroup>
<numbering type="journalVolume" number="5">5</numbering>
<numbering type="journalIssue">n1</numbering>
</numberingGroup>
<coverDate startDate="2010-07">July 2010</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="article" position="29" status="forIssue">
<doi origin="wiley">10.1111/j.1751-2824.2010.01423.x</doi>
<idGroup>
<id type="unit" value="VOXS1423"></id>
</idGroup>
<countGroup>
<count type="pageTotal" number="7"></count>
</countGroup>
<titleGroup>
<title type="tocHeading1">XXXIst International Congress of the ISBT, Berlin, Germany, 26 June‐1 July 2010</title>
<title type="tocHeading2">State of the Art Presentations</title>
</titleGroup>
<copyright>© 2010 The Author. Journal compilation © 2010 International Society of Blood Transfusion</copyright>
<eventGroup>
<event type="firstOnline" date="2010-06-10"></event>
<event type="publishedOnlineFinalForm" date="2010-06-10"></event>
<event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.9 mode:FullText" date="2010-06-11"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-10"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-23"></event>
</eventGroup>
<numberingGroup>
<numbering type="pageFirst" number="169">169</numbering>
<numbering type="pageLast" number="175">175</numbering>
</numberingGroup>
<correspondenceTo>J.‐P. Allain, Cambridge Blood Centre, Long Road, Cambridge CB2 2PT, Cambridge, UK
E‐mail:
<email>jpa1000@cam.ac.uk</email>
</correspondenceTo>
<linkGroup>
<link type="toTypesetVersion" href="file:VOXS.VOXS1423.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta>
<countGroup>
<count type="figureTotal" number="3"></count>
<count type="tableTotal" number="4"></count>
</countGroup>
<titleGroup>
<title type="main">Volunteer safer than replacement donor blood: a myth revealed by evidence</title>
<title type="shortAuthors">J.‐P. Allain</title>
<title type="short">A myth revealed by evidence</title>
</titleGroup>
<creators>
<creator creatorRole="author" xml:id="cr1" affiliationRef="#aff-1-1">
<personName>
<givenNames>J.‐P.</givenNames>
<familyName>Allain</familyName>
</personName>
</creator>
</creators>
<affiliationGroup>
<affiliation xml:id="aff-1-1" countryCode="GB">
<unparsedAffiliation>Transfusion Medicine, University of Cambridge, Cambridge, UK</unparsedAffiliation>
</affiliation>
</affiliationGroup>
<keywordGroup xml:lang="en">
<keyword xml:id="k1">blood donor</keyword>
<keyword xml:id="k2">blood supply</keyword>
<keyword xml:id="k3">replacement</keyword>
<keyword xml:id="k4">sub‐Saharan Africa</keyword>
<keyword xml:id="k5">volunteer</keyword>
</keywordGroup>
<abstractGroup>
<abstract type="main" xml:lang="en">
<p>The dogma that volunteer non‐remunerated blood donors (VNRD) are safer has been a cornerstone of world transfusion, including developing countries, for WHO and other major transfusion organizations although the data supporting this dogma has never been convincing. It was supported by data collected without regard for the basic rule of epidemiology, which is to compare what is comparable. In this case, first‐time and repeat VNRD were amalgamated, and genuine replacement/family donors (R/F) were mixed with paid donors. In sub‐Saharan Africa (SSA), VNRD and R/F donors have a median age of < 20 and around 30, respectively. In VNRD, the proportion of females is considerably higher than in R/F donors further distorting the comparisons. In epidemiological terms, only first‐time VNRD can be validly compared to R/F donors.</p>
<p>When such valid approach is taken, as published by three SSA countries (Cameroon, Ghana and Guinea), no significant difference in the prevalence of anti‐HIV and HBsAg is apparent. In each study, first‐time VNRD > 20 years of age have higher prevalence of HBsAg and sometimes of anti‐HIV than R/F donors. These confirmed preliminary data strongly suggest that first‐time VNRD and R/F donors are epidemiologically undistinguishable and equally safe for viral infections.</p>
<p>This collective data should directly impact three critical factors: the cost of blood, the availability of blood and the efforts put in recruiting repeat donors. R/F blood costs 2–5 times less than VNRD blood, and collecting R/F blood should no longer be discouraged. VNRD‐only policy not only costs more but also limits blood availability for acute anaemia, potentially endangering patients’ lives. Collecting R/F blood as a legitimate supplement to VNRD blood may help reaching 10 units/1000 inhabitants, a level considered adequate for developing countries’ blood supply.</p>
<p>Only repeat donation significantly improves blood viral safety. As a result, not only first‐time VNRD but also R/F donors should be actively encouraged to repeat donation. Evidence should take precedence over a moribund myth.</p>
</abstract>
</abstractGroup>
</contentMeta>
<noteGroup>
<note xml:id="artCateg-note" numbered="no">
<p>4D‐S28‐01</p>
</note>
</noteGroup>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6">
<titleInfo lang="en">
<title>Volunteer safer than replacement donor blood: a myth revealed by evidence</title>
</titleInfo>
<titleInfo type="abbreviated" lang="en">
<title>A myth revealed by evidence</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en">
<title>Volunteer safer than replacement donor blood: a myth revealed by evidence</title>
</titleInfo>
<name type="personal">
<namePart type="given">J.‐P.</namePart>
<namePart type="family">Allain</namePart>
<affiliation>Transfusion Medicine, University of Cambridge, Cambridge, UK</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="article" displayLabel="article"></genre>
<originInfo>
<publisher>Blackwell Publishing Ltd</publisher>
<place>
<placeTerm type="text">Oxford, UK</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2010-07</dateIssued>
<copyrightDate encoding="w3cdtf">2010</copyrightDate>
</originInfo>
<language>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription>
<internetMediaType>text/html</internetMediaType>
<extent unit="figures">3</extent>
<extent unit="tables">4</extent>
</physicalDescription>
<abstract lang="en">The dogma that volunteer non‐remunerated blood donors (VNRD) are safer has been a cornerstone of world transfusion, including developing countries, for WHO and other major transfusion organizations although the data supporting this dogma has never been convincing. It was supported by data collected without regard for the basic rule of epidemiology, which is to compare what is comparable. In this case, first‐time and repeat VNRD were amalgamated, and genuine replacement/family donors (R/F) were mixed with paid donors. In sub‐Saharan Africa (SSA), VNRD and R/F donors have a median age of < 20 and around 30, respectively. In VNRD, the proportion of females is considerably higher than in R/F donors further distorting the comparisons. In epidemiological terms, only first‐time VNRD can be validly compared to R/F donors. When such valid approach is taken, as published by three SSA countries (Cameroon, Ghana and Guinea), no significant difference in the prevalence of anti‐HIV and HBsAg is apparent. In each study, first‐time VNRD > 20 years of age have higher prevalence of HBsAg and sometimes of anti‐HIV than R/F donors. These confirmed preliminary data strongly suggest that first‐time VNRD and R/F donors are epidemiologically undistinguishable and equally safe for viral infections. This collective data should directly impact three critical factors: the cost of blood, the availability of blood and the efforts put in recruiting repeat donors. R/F blood costs 2–5 times less than VNRD blood, and collecting R/F blood should no longer be discouraged. VNRD‐only policy not only costs more but also limits blood availability for acute anaemia, potentially endangering patients’ lives. Collecting R/F blood as a legitimate supplement to VNRD blood may help reaching 10 units/1000 inhabitants, a level considered adequate for developing countries’ blood supply. Only repeat donation significantly improves blood viral safety. As a result, not only first‐time VNRD but also R/F donors should be actively encouraged to repeat donation. Evidence should take precedence over a moribund myth.</abstract>
<subject lang="en">
<genre>keywords</genre>
<topic>blood donor</topic>
<topic>blood supply</topic>
<topic>replacement</topic>
<topic>sub‐Saharan Africa</topic>
<topic>volunteer</topic>
</subject>
<relatedItem type="host">
<titleInfo>
<title>ISBT Science Series</title>
</titleInfo>
<genre type="journal">journal</genre>
<identifier type="ISSN">1751-2816</identifier>
<identifier type="eISSN">1751-2824</identifier>
<identifier type="DOI">10.1111/(ISSN)1751-2824</identifier>
<identifier type="PublisherID">VOXS</identifier>
<part>
<date>2010</date>
<detail type="title">
<title>XXXIst International Congress of the ISBT</title>
</detail>
<detail type="volume">
<caption>vol.</caption>
<number>5</number>
</detail>
<detail type="issue">
<caption>no.</caption>
<number>n1</number>
</detail>
<extent unit="pages">
<start>169</start>
<end>175</end>
<total>7</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">6F12C11EABAC980E09EB31EBAB890601CC468C10</identifier>
<identifier type="DOI">10.1111/j.1751-2824.2010.01423.x</identifier>
<identifier type="ArticleID">VOXS1423</identifier>
<accessCondition type="use and reproduction" contentType="copyright">© 2010 The Author. Journal compilation © 2010 International Society of Blood Transfusion</accessCondition>
<recordInfo>
<recordContentSource>WILEY</recordContentSource>
<recordOrigin>Blackwell Publishing Ltd</recordOrigin>
</recordInfo>
</mods>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000454 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000454 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaGhanaV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:6F12C11EABAC980E09EB31EBAB890601CC468C10
   |texte=   Volunteer safer than replacement donor blood: a myth revealed by evidence
}}

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Tue Nov 7 18:07:38 2017. Site generation: Tue Mar 5 15:01:57 2024